2 transcripts
SDGR
Earnings call transcript
NASDAQ
2023 Q4
28 Feb 24
SGR-1505, during our recent Pipeline Day, we reported that SGR-1505 was well tolerated in a completed Phase I study of 73 healthy volunteers. No drug
SDGR
Earnings call transcript
NASDAQ
2023 Q2
2 Aug 23
recruitment objectives. We are conducting a Phase 1 healthy volunteer study designed to generate additional data on the profile of SGR-1505. We plan
- Prev
- 1
- Next